NASDAQ · Biotechnology

Polyrizon Ltd. (PLRZ) Stock

$8.73 +0.05% NASDAQ: PLRZ Healthcare

Valuation

MetricValue
Price$8.73
Market Cap$9.77M
P/E Ratio-2.28
P/B Ratio0.71
P/S Ratio0.00
EPS (TTM)$-2.07
52-Week High$18.20
52-Week Low$2.88
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-22.45%
ROA-19.14%
ROCE-43.31%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio29.03

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-1.0M$-1.0M$-1.0M$-1.0M$-6.0M
Net Profit$-1.0M$-1.0M$-1.0M$-2.0M$-3.0M
EPS$0.00$0.00$0.00$-134.14$-2.07
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.0M$1.0M$1.0M$6.0M$21.0M
Total Liabilities$1.0M$1.0M$1.0M$0$0
Cash$1.0M$0$0$3.0M$1.0M
Borrowings$0$0$0$0$0

Latest News

Polyrizon shares climb after NASARIX passes key biocompatibility testing (PLRZ) InvestorsHub · Jul 2, 2026 Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial GlobeNewswire · Jul 2, 2026 Polyrizon Receives Approval for Human Trial of Nasarix Nasal Spray for Allergic Rhinitis MT Newswires · Jun 29, 2026 Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial GlobeNewswire · Jun 29, 2026 Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform GlobeNewswire · Jun 17, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$0$-1.0M$-1.0M$-1.0M$-5.0M
Investing Cash Flow$0$0$0$0$-17.0M
Financing Cash Flow$0$-1.0M$0$0$0
Net Cash Flow$1.0M$0$0$3.0M$-1.0M
Free Cash Flow$-1.0M$-1.0M$-1.0M$-1.0M$-5.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.01
EV / EBITDA-0.23
FCF Yield-55.99%
Quick Ratio36.37
Interest Coverage-3.36
Return 1Y109.46%
Return 3Y—
Return 5Y—

Ownership

Insiders Held0.83%
Institutions Held7.13%
Institutions Float Held7.19%
Institutional HolderSharesReport Date
Citadel Advisors Llc10,1492026-03-31
Legacy Wealth Managment, LLC/ID1,1502026-03-31
Citigroup Inc.12026-03-31

About Polyrizon Ltd.

Polyrizon Ltd. is led by CEO Tomer Izraeli, employs 2 people, headquartered in IL, publicly traded since 2024.

Polyrizon Ltd. (PLRZ) stock trades at $8.73 with a market capitalization of $9.77M. The stock is valued at a negative price-to-earnings (P/E) ratio of -2.28, reflecting a net loss over the last twelve months, price-to-book of 0.71, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.88 and $18.20, and currently trades 52.0% below its 52-week high.

On profitability, Polyrizon Ltd. generates a return on equity (ROE) of -22.45% (negative, reflecting a net loss), return on capital employed of -43.31%.

Polyrizon Ltd. by the numbers, 2020–2025

Between 2020 and 2025 Polyrizon Ltd. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit was $-3.0M in 2025.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-4.0M.

Borrowings stand at $0, cash from operations was $-5.0M in the latest year, positive in 0 of the last 6.

Return on equity has averaged 15.2% over five years, and was -14.3% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Polyrizon Ltd. (PLRZ) — frequently asked questions

What is Polyrizon Ltd. (PLRZ) stock price today?

Polyrizon Ltd. (PLRZ) is currently trading at $8.73, up 0.05% today.

What is PLRZ P/E ratio?

Polyrizon Ltd.'s P/E ratio is -2.28. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is PLRZ return on equity (ROE)?

Polyrizon Ltd.'s return on equity (ROE) is -22.45%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is Polyrizon Ltd.'s market cap?

Polyrizon Ltd. has a market capitalization of $9.77M.

Does PLRZ pay a dividend?

Polyrizon Ltd. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does PLRZ carry?

Polyrizon Ltd. has a debt-to-equity ratio of 0.00. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is PLRZ's profit margin?

Polyrizon Ltd. reports a net profit margin of 0.00% — the share of revenue left after every cost, including tax and interest.

What sector is PLRZ in?

Polyrizon Ltd. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is PLRZ listed on?

Polyrizon Ltd. trades on NASDAQ under the ticker PLRZ.

What is PLRZ's 52-week range?

Over the last year Polyrizon Ltd. has traded between $2.88 and $18.20.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens PLRZ currently matches

On the figures above, Polyrizon Ltd. passes the filters for 2 of our ready-made screens, among them Debt Free Stocks Under $100, Nano Cap Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Debt Free Stocks Under $100Nano Cap Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.